C
ardiac allograft vasculopathy (CAV) is reported to affect 50% of heart transplantation (HTx) recipients within 5 years after transplantation 1 and is the second leading cause of post-HTx mortality. 1 Prevention of CAV remains a significant clinical challenge as the widespread use of powerful immunosuppressive agents including calcineurin inhibitors (CNI), such as cyclosporine A or tacrolimus, do not seem to ameliorate CAV development. 2 In fact, the use of CNI agents is associated with adverse effects, including metabolic disturbances (eg, new onset diabetes mellitus) and renal toxicity, 3 which may negatively influence CAV development. 4 An alternative immunosuppressive protocol providing sufficient immune modulation without such adverse effects and with potential attenuating effects on CAV development is, therefore, an ideal but elusive goal in HTx.
During the last decade, immunosuppressive drugs inhibiting the mammalian target of rapamycin signaling pathway have received considerable attention. Everolimus is a mammalian target of rapamycin inhibitor that arrests the cell cycle of lymphocytes and vascular smooth cells in the G1 phase, 5 and this combined immunosuppressive and antiproliferative effect is relevant to CAV development. It has previously been demonstrated that everolimus initiation in de novo HTx recipients with standard or reduced CNI therapy can attenuate intimal thickening of coronary arteries. [6] [7] [8] We demonstrated in the 12-month SCHEDULE study (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) that de novo everolimus therapy and early elimination of CNI therapy is also feasible and reduces the early progression (ie, 12 months) of CAV. 9 Furthermore, such a CNI-free strategy is associated with improved renal function at 12 months, 10 and a beneficial effect on renal function and coronary artery intimal thickness is maintained at 36 months. 11 The purpose of the current report of the SCHEDULE trial is to provide an in-depth evaluation of the effect of everolimus initiation and CNI elimination on CAV at 36 months by utilizing percent atheroma volume (PAV) and total atheroma volume (TAV) as alternative end points to maximal intimal thickness (MIT), as well as angiographic data. Inflammatory marker measurement was also performed in parallel to evaluate underlying inflammatory pathways that could potentially mediate any observed intimal changes associated with everolimus therapy. Finally, the current report also provides qualitative assessment of plaque morphology by virtual histology (VH) analysis at 12 and 36 months after randomization.
METHODS

Patient Population
A detailed description of the SCHEDULE trial has been reported previously. 10 In brief, the SCHEDULE trial was a 12-month prospective, open-label, multicenter, randomized controlled study undertaken at 5 HTx centers in Scandinavia. Adult de novo HTx recipients were randomized in a 1:1 ratio to (1) low-dose everolimus, low-dose cyclosporine, mycophenolate mofetil (MMF), and corticosteroids with elimination of cyclosporine and step up to full-dose everolimus after 7 to 11 weeks or (2) conventional treatment with cyclosporine, MMF, and corticosteroids. All patients received the first dose of everolimus, cyclosporine, MMF, and corticosteroids no later than the fifth postoperative day. The current report is 36-month continuation of the original SCHEDULE study evaluating CAV progression. The first SCHEDULE visit was performed in December 2009, and the final-month 36 follow-up visit took place in November 2014. Written informed consent was obtained from all patients. The study was approved by the regional ethical authority in each country and was performed in accordance with the ICH Harmonized Tripartite Guidelines
WHAT IS NEW?
• 
WHAT ARE THE CLINICAL IMPLICATIONS?
• There is currently no effective medical therapy for cardiac allograft vasculopathy after heart transplantation. Everolimus and total early cyclosporine elimination had a beneficial effect on cardiac allograft vasculopathy progression after heart transplantation, and such therapy could potentially improve long-term outcome after heart transplantation.
• Everolimus initiation and total early cyclosporine elimination does not seem to have any detrimental effect on cardiac allograft vasculopathy morphology or immune marker activity. This immunosuppressive protocol also has an additional beneficial effect on renal function, highlighting the advantage of considering such therapy early after heart transplantation.
for Good Clinical Practice, applicable local regulations, and the Declaration of Helsinki and was registered. Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the corresponding author and will be subject to approval from the steering committee.
IMMUNOSUPPRESSIVE MEDICATION
All patients received induction treatment with antithymocyte globulin (Thymoglobulin, Genzyme Corporation, Cambridge, MA) within 12 hours of HTx, and this continued for up to 5 days. In the everolimus group, everolimus was initiated at a dose of 0.75 mg twice daily, no later than the fifth postoperative day, and cyclosporine elimination took place at week 7 unless there was ongoing rejection at that time, in which case discontinuation was allowed to be postponed up to week 11. All patients received statin therapy, and patients who were seronegative for cytomegalovirus and received a graft from a cytomegalovirus-positive donor were given prophylaxis with oral valganciclovir for at least 3 months according to the local protocol.
Intravascular Ultrasound Imaging
The SCHEDULE trial protocol specified intravascular ultrasound (IVUS) examination of the same major epicardial coronary artery (preferentially the left-anterior descending coronary artery), and this was conducted while performing coronary angiography at week 7 to 11, 12 months, and 36 months post-HTx using a 20-MHz, 2.9F, monorail electronic Eagle Eye Gold IVUS catheter (Volcano Corporation Inc, CA). Patients with severe renal impairment (as judged by the principal investigator but generally considered as glomerular filtration rate <30 mL/min per 1.73 m 2 ) were to be excluded from IVUS study (because of the risk of angiographic contrast), but no patients had this level of renal impairment, and, hence, this exclusion criterion did not apply to any of the randomized patients. IVUS images were acquired at a rate of 30 frames/s and pullback speed of 0.5 mm/s. Images were stored digitally for off-line analysis conducted after trial closure by a core laboratory (Oslo University Hospital, Rikshospitalet, Oslo, Norway) blinded to patient treatment. IVUS analysis was performed according to the guidelines for acquisition and analysis of IVUS images by the American College of Cardiology and European Society of Cardiology. 12 Precise matching of the IVUS recordings was performed followed by contour detection of both the lumen and external elastic membrane at ≈1 mm intervals using validated software (QIVUS, v.3.0, Medis Medical Imaging Systems, Leiden, The Netherlands).
Grayscale IVUS Analysis
MIT is an established predictor of all-cause mortality, myocardial infarction, and angiographic abnormalities among HTx recipients. 13, 14 Hence, change in MIT between matching segments at baseline and 12 and 36 months was utilized as the primary grayscale IVUS efficacy variable. Other secondary IVUS variables were (1) PAV which expresses the summation of atheroma areas in proportion to the external elastic membrane area using the equation PAV=∑ (external elastic membrane area −Lumen area )/∑external elastic membrane area )×100, (2) normalized TAV, and (3) incidence of CAV (defined as mean MIT ≥0.5 mm over the entire matched segment). The mean length of analyzed segments at baseline, 12 months, and 36 months was 36.7±7.3, 36.4±8.1, and 36.8±10.5 mm, respectively.
Angiographic Assessment of CAV
Coronary artery angiogram data were evaluated by experienced local staff blinded to treatment and were reported according to the International Society for Heart and Lung Transplantation standardized nomenclature for CAV.
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VH Analysis
VH (Volcano Corporation Inc, Rancho Cordova, CA) is a technological tool that utilizes backscatter radiofrequency data obtained during IVUS pullback for qualitative plaque assessment. VH-IVUS possesses 94% to 97% ex vivo and 87% to 97% in vivo accuracy for characterization of basic tissue components. 16, 17 VH-IVUS data obtained at baseline and 12 and 36 months were analyzed with validated software (QIVUS, v.3.0) that reconstructs tissue maps with 4 identifiable major components (fibrous, fibrofatty, dense calcified, and necrotic core components) based on mathematical autoregressive spectral analysis of backscattered radiofrequency data. The various tissue components are expressed as a percentage of total intima and media area.
Inflammatory Marker Analysis
In total, 65 patients (from 2 centers) underwent plasma sampling by standard venipuncture at baseline and 12 and 36 months. Plasma levels of VCAM-1 (vascular cell adhesion molecule-1), ICAM-1 (intercellular adhesion molecule-1), the CXC chemokine CXCL16, and sTNFR-1 (soluble tumor necrosis factor receptor-1) were measured by enzyme immunoassays (R&D Systems, Minneapolis, MN). Plasma levels of CRP (C-reactive protein) and VWF (von Willebrand factor) were measured by enzyme immunoassays as previously described. 18 All intra-assay and interassay coefficients of variance were <10%.
Statistical Analysis
Analyses were performed with the SPSS v 22.0 statistical software (SPSS Inc, Chicago, IL). Data are expressed as mean±SD, and a 2-tailed P value <0.05 was considered statistically significant. Baseline characteristics were compared using Student t test, Mann-Whitney test, and Pearson's χ 2 test as appropriate. Pearson's χ 2 test was used to compare the incidence of acute rejection, and the Cochran-Mantel-Haenszel test was utilized to compare the 36-month incidence of CAV in the treatment groups (adjusted for baseline CAV). Changes in IVUS end points were compared between treatment groups by performing ANCOVA, with the baseline IVUS value included as a covariate and treatment group as a fixed factor. ANCOVA P values represent between-group contrast. Multivariate regression analysis was performed to identify predictors of CAV progression after an initial exploratory univariate analysis that selected potentially relevant covariates (P value <0.05). Multivariable regression analysis was performed using the forward stepwise method with criteria for entry and exit at P<0.05 and <0.10, respectively. Change in inflammatory marker values was compared between treatment groups by ANCOVA analysis of logtransformed data.
RESULTS
Patient Population
Of the 115 patients randomized in the SCHEDULE study, 76 (66%) patients had matching IVUS recordings at baseline and 12 and 36 months, with a similar number between both treatment groups (39 everolimus versus 37 controls; Figure 1 ). Fifty-one (44%) patients had matching VH-IVUS recordings at these 3 timepoints. Overall, 10 (9%) patients died during the 36-month follow-up period. There were 7 deaths in the cyclosporine group with cause of death recorded as cerebrovascular accident, sepsis, cardiac arrest, sudden death, graft loss, and 2 cases of malignancy. There were 3 deaths in the everolimus group with cause of death recorded as graft failure, pleural hemorrhage, and malignancy.
Mean age of patients in the 36-month IVUS study population was 50.8±12.1 years, and there was no significant difference in baseline characteristics between the treatment groups ( Table 1 ). There was no significant difference in baseline characteristics when comparing the 76 IVUS patients with the total SCHEDULE population (n=115; glomerular filtration rate in IVUS population was 59.7 mL/min per 1.73 m 2 as compared with 60.7 mL/min per 1.73 m 2 in the total SCHEDULE population [P=0.41]-remaining data not shown).
IMMUNOSUPPRESSION
All patients in the everolimus group discontinued cyclosporine at week 7 to 11 according to the trial protocol. The mean everolimus trough level at 12 and 36 months was 7.9±3.8 and 6.9±2.1 ng/mL, respectively. In the everolimus group, 6 (16%) patients resumed low-dose cyclosporine in combination with everolimus, while 6 (16%) patients discontinued everolimus permanently because of adverse effects. Among the 39 control patients, 5 (13%) patients were switched from cyclosporine to everolimus therapy because of deteriorating renal function. There were, therefore, 59 patients in the per protocol population.
Acute Rejection
The incidence of biopsy-proven acute rejection during the first 12 months was 78.4% in the everolimus group versus 56.4% in the cyclosporine group (P=0.14). The vast majority of rejection episodes ≥2R occurred during the first 12 months, with only 7 episodes occurring in the 12-to 36-month period. These episodes occurred in 6 patients of whom 5 had previously experienced similar rejection episodes (≥2R) during the first 12 months. Overall, at 36 months, the number of patients with rejection graded ≥2R was 15 (41%) in the everolimus group as compared with 5 (13%) in the cyclosporine group (P=0.01). Rejection treatment consisted of corticosteroids in all cases without the need for cytolytic agents. No cases of humoral rejection or rejection with hemodynamic compromise were observed in the 36-month IVUS study population.
GRAYSCALE IVUS OUTCOME
Only patients with exact matching IVUS recordings at baseline and 12 and 36 months (n=76) are considered in the current IVUS report. As reported previously, grayscale IVUS at 12 months demonstrated that everolimus patients had a mean increase in MIT of 0.02±0.05 mm as compared with 0.08±0.11 mm among cyclosporine patients (P<0.01; Figure 2 ). This effect of everolimus persisted at 36 months, with a total mean increase in MIT of 0.09±0.05 mm as compared with 0.15±0.16 mm among cyclosporine patients (P=0.03; 36-month values compared with baseline; Figure 2 ). In the current study, a similar pattern was seen for PAV, with a significantly smaller mean increase among everolimus patients ( Figure 2 ).
The number of everolimus patients defined as having CAV (mean MIT ≥0.50 mm) increased from 12 (32%) at baseline to 16 (43.2%) at 36 months as compared with an increase from 10 (26%) to 21 (53.8%) patients in the cyclosporine arm (P=0.10 when analyzing differences in changes). Multivariable stepwise regression analysis was performed with the following 5 candidate variables: recipient age, donor age, everolimus, sex, and diabetes mellitus. Of these variables, recipient sex, donor age, and treatment with everolimus were selected as independent predictors of CAV progression, with everolimus having an independent adjusted treatment effect of B=−0.04 (95% CI, −0.10 to 0.01) mm (P=0.03; Table 2 ).
Cytomegalovirus infection/viremia did not influence CAV progression as evidenced by nearly identical disease progression in patients with and without cytomegalovirus infection/viremia (ΔMIT, PAV, and TAV at 36 months 0.12±0.13 mm, 6.4±5.0%, and 41.9±89.2 mm 3 versus 0.12±0.13 mm, 6.5±5.0%, and 59.2±65.4 mm3, respectively; all P values >0.05).
Per-Protocol Grayscale IVUS Analysis
Analysis of grayscale IVUS recordings was also performed in the per-protocol population, which excluded 17 patients (12 in the everolimus and 5 in cyclosporine arm) where treatment according to randomization arm was not followed. Mean increase in MIT at 36 months in the everolimus group was 0.09±0.05 mm as compared with 0.16±0.17 mm in the cyclosporine arm (P=0.04). ΔPAV and ΔTAV in everolimus patients were 4.9±2.8% and 15.9±47.3 mm 3 as compared with 8.0±6.0% (P=0.02) and 59.3±101.0 mm 3 (P=0.05) in the cyclosporine group, respectively.
Angiographic Assessment of CAV
The number of everolimus patients with angiographic CAV increased from 4 (10.8%; all CAV 1 ) to 10 (27.0%; 
CAV Progression at 36 Months According to Presence of Donor Disease
When utilizing baseline mean MIT ≥0.50 mm as the threshold for defining donor disease 19 (ie, atherosclerosis), we noted that 54 patients (25 everolimus and 29 cyclosporine) did not have donor disease. There was a beneficial effect of everolimus in this subgroup of patients, and mean ∆MIT at 36 months was 0.08±0.05 and 0.15±0.16 mm in the everolimus and cyclosporine group, respectively (P=0.03; Figure 3 ). The alternative end point PAV confirmed a significant beneficial between the 2 treatment arms (∆PAV at 36 months 4.5±2.7 and 7.7±6.1 mm in the everolimus and cyclosporine group, respectively), whereas TAV did not show a significant difference between the 2 groups (Figure 3) . Among 22 patients with donor disease (12 everolimus and 10 cyclosporine), the 3 independent IVUS end points MIT, PAV, and TAV demonstrated similar disease progression in both treatment groups (Figure 3) .
VH Analysis
VH analysis of matched VH-IVUS recordings at baseline and 12 and 36 months revealed no significant difference in change in plaque morphology according to treatment group. Overall, the increase in fibrotic, fibrofatty, calcified, and necrotic tissue during the 36-month period everolimus group was −7.4±12.8%, 9.6±10.9%, 0.0±8.4%, and −2.6±9.1% in the everolimus group, as compared with 0.3±12.9%, 7.4±14.7%, −3.5±8.3%, and −4.5±9.8% in the cyclosporine group, respectively (all P values >0.05; Figure 4 ).
Immune Marker Profile
There was a significant decline in levels of all measured inflammatory markers from baseline to 36 months, but there was no significant difference between the 2 treatment groups (Table 3) . A post hoc analysis was per- formed to evaluate the change in inflammatory marker levels according to rapid CAV progression (ΔMIT ≥0.10 mm), but there was no evidence of a relationship between these biomarkers and increased CAV (data not shown). A separate post hoc analysis found no significant difference in change in levels of inflammatory among everolimus patients with and without 2R rejection episodes (all P values >0.05).
DISCUSSION
The current follow-up of de novo HTx recipients in the SCHEDULE trial has demonstrated that everolimus initiation and early CNI elimination reduces CAV progression at 12 months, and this beneficial effect is sustained at 36 months. This immunosuppressive approach is safe as demonstrated by similar cardiac function and low mortality in both treatment groups, despite the difference in biopsy-verified acute rejection rate. 10, 11 Furthermore, VH analysis confirmed that everolimus initiation and CNI withdrawal is not associated with any significant increase in inflammatory tissue components (calcified and necrotic tissue) or systemic inflammatory markers.
CAV is an important complication after HTx. Although CNI therapy is a pillar of current immunosuppressive protocols, the effect of such agents on CAV is limited and may potentially have a detrimental effect on disease progression. 20 The mammalian target of rapamycin inhibitor everolimus is an immunosuppressive agent with additional effects that could be of interest in relation to CAV (ie, antiproliferative and antifi- demonstrated that everolimus instead of azathioprine together with background CNI therapy reduces CAV among de novo HTx recipients. Similarly, another trial evaluating CAV in the de novo setting demonstrated a beneficial effect of everolimus and reduced CNI as compared with MMF and standard CNI therapy. 7 In contrast, the NOCTET trial 21 (Nordic Certican Trial in Heart and Lung Transplantation) among maintenance HTx recipients failed to demonstrate a beneficial effect of everolimus and reduced CNI therapy on CAV, although a beneficial effect was seen in those who received azathioprine but not in those receiving MMF.
The SCHEDULE trial is the first to investigate the use of everolimus with early CNI elimination showing that this immunosuppressive approach significantly reduces CAV progression at 12 and 36 months. As reported previously, everolimus initiation and CNI elimination markedly improved renal function with a significant increase in measured glomerular filtration rate in the everolimus group. 10, 11 The association between early intimal thickening and adverse prognosis has previously been established among HTx recipients. 13, 14 Similarly, there is sizeable data indicating that declining renal function after HTx is associated with increased morbidity and mortality. 4, 22 Hence, everolimus initiation and early CNI elimination in de novo HTx recipients seems to have a dual beneficial advantage on CAV and renal function that may have a positive and potential synergistic impact on long-term clinical outcome, although this remains to be demonstrated.
Our post hoc analysis of CAV progression according to the presence of donor disease revealed that everolimus only attenuates intimal thickening in patients without underlying donor disease. Everolimus was unable to influence progression of CAV in the setting of preexisting donor disease. However, it should be noted that our study had a relatively younger donor age as compared with previous studies, 14 and, hence, this negative finding is based on a relatively small cohort of patients with donor disease. Despite the possibility of a type 2 error, our results indicate the need to consider everolimus at the earliest possible timepoint after HTx. Our results suggest that a certain window of opportunity is likely to exist where everolimus has a beneficial effect on intimal thickening as supported by the NOCTET results 21 where everolimus did not influence CAV progression among maintenance recipients.
Everolimus is a mammalian target of rapamycin inhibitor that has been shown to possess both antiproliferative and antifibrotic effect in addition to its immunomodulatory properties 23 and, hence, may have a qualitative effect on intimal thickening. The current study, however, demonstrated that everolimus does not significantly influence intimal tissue composition as compared with traditional immunosuppression. The proportion of inflammatory tissue components remained unchanged in both treatment groups, and a similar pattern was also seen in markers of systemic inflammation. This neutral finding is in contrast to the previous NOCTET reporting increased inflammatory tissue in maintenance recipients treated with everolimus. 21 Hence, the effect of everolimus on CAV in the current study is primarily manifested by the observed quantitative decrease in intimal tissue (measured by grayscale IVUS) without any significant morphological changes (measured by VH). Moreover, the beneficial effects of everolimus on CAV seem unrelated to its anti-inflammatory properties as a similar anti-inflammatory effect was seen during CNI treatment both within the lesion and systemically.
According to the SCHEDULE trial, patients in the everolimus arm received both CNI and everolimus until week 7. We found no association between the measured systemic inflammatory markers and CAV progression. Nevertheless, it remains possible that the increased intensity of immunosuppression coupled with antilymphocyte induction during the early period had a positive influence on inflammation and CAV and should be explored further. The everolimus arm was noted to experience a significantly greater number of grade 2R rejections, and this could potentially mitigate a reduction in systemic inflammation attributable to everolimus. With reference to this, a post hoc analysis found no significant difference in change in levels of inflammatory among everolimus patients with and without 2R rejection episodes (all P values >0.05), indicating that cellular rejection did not influence systemic markers of inflammation measured at 36 months.
The current immune marker results are in contrast to previously reported studies [24] [25] [26] [27] demonstrating a clear association between these diverse makers and traditional atherosclerosis, further supporting the notion that the pathophysiology of CAV is distinctly different from native atherosclerosis. 28 Nonetheless, the neutral effect of everolimus in this study (de novo recipients) as compared with the increased inflammatory effect in the NOCTET study (maintenance HTx) further suggest that early intervention with everolimus is preferable.
The present study has some limitations. Imaging of the left ascending artery was used as a surrogate for all potential CAV that may be present. The number of patients was relatively small in certain subanalyses, including the evaluation of everolimus according to presence/absence of donor disease, as well as assessment of systemic inflammatory markers particularly among patients with and without 2R rejection. Angiographic assessment of CAV did not reveal any benefit of everolimus, but it should be noted that a 3-year followup may be too short a time to observe such a benefit.
The relative homogeneous study population in this Scandinavian cohort of predominantly male white patients should also be noted. Data about cause of death was available for all mortality cases, but histology of the coronary arteries of these patients would have been beneficial. Despite these limitations, the authors think that the data are robust and particularly relevant to clinical practice as it provides the longest CAV followup period to date among de novo HTx patients treated with everolimus.
In conclusion, this 36-month follow-up of the SCHEDULE trial has confirmed that the beneficial effect of everolimus on CAV at 12 months is maintained at 36 months. The benefit of everolimus was not evident among a small cohort of patients, with established donor-transmitted disease suggesting that early use of this agent is likely to be more effective. There is no evidence of everolimus having a detrimental effect on CAV morphology or immune marker activity during this follow-up period even if the number of grade 2R rejections was increased in the everolimus group. Given these positive findings, coupled with the beneficial effect of everolimus on renal function during the same follow-up period, it seems that everolimus and early CNI withdrawal is an attractive alternative immunosuppressive protocol that may improve long-term outcome after HTx. The beneficial effect of everolimus on CAV may involve antifibrotic and antiproliferative effect, but at present, its mechanisms of action on CAV development seem elusive.
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